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Abstract
Background: To determine whether the dose-volume histograms (DVH's) for the rectum and
bladder constructed using biological-effective dose (BED-DVH's) better correlate with late
gastrointestinal (GI) and genitourinary (GU) toxicity after treatment with external beam
radiotherapy for prostate cancer than conventional DVH's (C-DVH's).
Methods: The charts of 190 patients treated with external beam radiotherapy with a minimum
follow-up of 2 years were reviewed. Six patients (3.2%) were found to have RTOG grade 3 GI
toxicity, and similarly 6 patients (3.2%) were found to have RTOG grade 3 GU toxicity. Average
late C-DVH's and BED-DVH's of the bladder and rectum were computed for these patients as well
as for matched-pair control patients. For each matched pair the following measures of normalized
difference in the DVH's were computed: (a) δAUC = (Area Under Curve [AUC] in grade 3 patient
– AUC in grade 0 patient)/(AUC in grade 0 patient) and (b) δV60 = (Percent volume receiving = 60
Gy [V60] in grade 3 patient – V60 in grade 0 patient)/(V60 in grade 0 patient).
Results: As expected, the grade 3 curve is to the right of and above the grade 0 curve for all four
sets of average DVH's – suggesting that both the C-DVH and the BED-DVH can be used for
predicting late toxicity. δAUC was higher for the BED-DVH's than for the C-DVH's – 0.27 vs 0.23
(p = 0.036) for the rectum and 0.24 vs 0.20 (p = 0.065) for the bladder. δV60 was also higher for
the BED-DVH's than for the C-DVH's – 2.73 vs 1.49 for the rectum (p = 0.021) and 1.64 vs 0.71
(p = 0.021) for the bladder.
Conclusions:  When considering well-established dosimetric endpoints used in evaluating
treatment plans, BED-DVH's for the rectum and bladder correlate better with late toxicity than C-
DVH's and should be considered when attempting to minimize late GI and GU toxicity after
external beam radiotherapy for prostate cancer.
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Background
Radiotherapy treatment planning is, in broad terms, the
process of planning the delivery of a prescribed dose to a
tumor or target volume while minimizing dose to the sur-
rounding critical structures. Prior to the modern radio-
therapy treatment planning era, the 'optimum' plan was
decided upon using qualitative criteria, or by estimating
the inhomogeneity of the dose in the target or in critical
regions. With the advent of CT-based planning, the plan-
ning process could be done with increased precision, as 3-
dimensional structures representing the target and critical
structures could be defined more accurately and reproduc-
ibly. One of the most useful tools which emerged in the 3-
dimensional planning era that could be used in establish-
ing the acceptability or unacceptability of a treatment plan
is the dose-volume histogram (DVH) [1].
The DVH is used ubiquitously and plots delivered dose on
the x-axis and percent volume of the structure of interest
on the y-axis. The general shape and area under the DVH
curve is instrumental in determining adequate coverage
and homogeneity of dose in the target volume as well as
in determining acceptable dose to critical structures. In-
deed, the DVH has occupied a central role in modern
treatment planning [2–5].
The DVH is not without its limitations, however. First,
there is an inherent loss of spatial information with the
construction of a DVH plot. Second, the dose plotted on
the x-axis of a conventional DVH (C-DVH) is convention-
al dose, which does not take into account many factors in-
fluencing the effects of the dose on the given tissue.
Among them are the α/β of the structure (which can vary
considerably for early vs late reacting tissues and for early
vs late reactions within the same tissue), time taken to de-
liver treatment, fraction size, and length of treatment in-
terruptions. For this reason, the concept of biological-
effective dose (BED) was developed [6,7] and has been
studied extensively by the radiobiology community. Be-
cause the BED incorporates factors related to delivery of
treatment and tissue factors, it is a better representation of
the dose delivered to a given tissue than conventional
dose [6–8].
The application of BED has particular importance to radi-
ation treatment planning for prostate cancer. The prostate,
more so than any other disease site, has been the focus of
advances in treatment delivery technique. The prostate
has been the paradigm site for treatment planning efforts
related to conformal therapy [9–12] and intensity modu-
lated radiotherapy (IMRT)/inverse planning [13,14]. Also,
the prostate has been the leading disease site for efforts re-
lated to improving daily setup [15] and incorporating or-
gan motion into the delivery strategy [16]. These above
efforts have allowed for dose escalation of the prostate
while minimizing early and late treatment toxicity [9–
14,17].
In view of the lead role the prostate has taken in under-
standing treatment planning, patient setup, and dose es-
calation, incorporation of treatment-related information
into the DVH – to further facilitate advances in reduction
of rectal or urinary toxicity – is highly appropriate. The
purpose of the current investigation is to compare C-
DVH's of the bladder and rectum in those patients who
developed late treatment toxicity versus those patients
who did not develop such toxicity, and, using the same
groups of patients, to determine whether the biological-
effective DVH (BED-DVH) can potentially serve as a better
tool for such toxicity comparisons than the C-DVH.
Methods
A generalized theoretical model for determination of bio-
logical effective dose has been developed and reported ex-
tensively [6–8]. Recently, our group has applied this
model for use with any combination of short-lived inter-
stitial brachytherapy and external beam radiotherapy for
prostate cancer (unpublished/submitted data, 2003). For
external beam radiotherapy, the generalized BED model
reduces to the familiar equation:
BED = [n*d(1 + d/(α/β))] - [(0.693*T)/(α*Tp)]   (1)
where n = number of treatments, d = dose per fraction, T
= treatment time, α/β = 3 Gy(for late effects), and Tp (po-
tential doubling time) and α (linear component of cell
killing) were estimated from the published literature [6–
8],[18,19] to be 34 days and 0.3/Gy, respectively. The first
term in Equation (1) accounts for dose fractionation and
the second term accounts for repopulation. The authors
recognize that there is considerable controversy in the ex-
act values used for α/β, α, and Tp for prostate cancer in the
reported literature.
The charts of 190 consecutive patients with T1 or T2 pros-
tate cancer treated with external beam radiotherapy at our
institution between 1996–1999 were reviewed. During
this period, external beam radiotherapy was delivered us-
ing 6-field technique, once daily, 5 times a week, using
180 cGy or 200 cGy fractions, to a final dose of 7000–
7200 cGy (minimum PTV dose). The conformal tech-
niques at our institution have been previously reported
[20] – the prostate, seminal vesicles, rectum, and bladder
were outlined routinely on all patients, and uniform
guidelines were adhered to in order to minimize inter-ob-
server variability in the definition of these structures. In
particular, with regard to the rectum, our institution fol-
lowed routine Radiation Therapy Oncology Group
(RTOG) guidelines for definition – from the anus at the
level of the ischial tuberosities {lower border} to theBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/16
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rectosigmoid junction {upper border} [21]. The bladder
was contoured from the apex to the dome, again as out-
lined per RTOG guidelines. The planning target volume
(PTV) was the prostate + seminal vesicles + 1 cm margin
for the initial phase; after 4500–5000 cGy, the PTV was
the prostate + 1 cm margin. Corresponding DVH's were
computed for the PTV, entire rectum (i.e., not the rectal
wall or rectal surface), and entire bladder (again, not the
bladder wall or bladder surface). The dose-fractionation
and total treatment time for each patient were recorded to
obtain values for n, d, and T in Equation (1) above.
No charts for those patients treated after 1999 were re-
viewed to ensure long minimum follow-up. At each rou-
tine follow-up, the GI and GU complications using
definitions and grading as stated by the RTOG [22] were
recorded. Thus, the charts were reviewed to identify those
patients with significant (RTOG grade 3 or grade 4) late GI
(large bowel) or GU (bladder) complications.
Of the 190 patients, 6 patients (3.2%) were found to have
late grade 3 rectal toxicity and 6 patients (3.2%) were
found to have late grade 3 urinary toxicity. No patients
were found to have grade 4 GI or GU toxicity. A matched-
pair group of patients (6 GI and 6 GU) with grade 0 toxic-
ity having similar pretreatment (age, stage, grade, and
PSA) and treatment (technique and dose) characteristics
were identified from the same patient database. The char-
acteristics of the groups are shown in comparison with the
groups of patients demonstrating toxicity in Tables 1 and
Table 1: Characteristics of groups having grade 3 vs grade 0 rectal (GI) toxicity
Grade 3 group Grade 0 group




Mean Age (yr) 70.8 69.4





180 cGy 1 1
200 cGy 5 5
Technique (number)
6-Field 6 6
Mean Dose (cGy) 7170 7167
Table 2: Characteristics of groups having grade 3 vs grade 0 urinary (GU) toxicity
Grade 3 group Grade 0 group




Mean Age (yr) 70.4 69.7





180 cGy 0 0
200 cGy 6 6
Technique (number)
6-Field 6 6
Mean Dose (cGy) 7170 7200BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/16
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2. The limitations and potential biases inherent to a
matched-pair comparison are well-understood by the au-
thors; however, as these tables demonstrate, there is no
difference in the pretreatment and treatment characteris-
tics between the groups demonstrating and not demon-
strating GI [Table 1] and GU [Table 2] toxicity.
The C-DVH's were already constructed (prior to undertak-
ing the current investigation) for the patients in each of
the four groups (grade 0 – rectal, grade 3 – rectal, grade 0
– bladder, grade 3 – bladder) – these are the C-DVH's that
were approved by the attending radiation oncologist prior
to delivering the external beam treatment. Then, these C-
DVH's derived from each of the individual dose distribu-
tions were averaged over the six patients in each of the
four groups (grade 0 – rectal, grade 3 – rectal, grade 0 –
bladder, and grade 3 – bladder) to produce average C-
DVH's.
Using equation (1), the time-dose fractionation parame-
ters were incorporated to transform the conventional dose
to BED at each conventional dose level. This allowed for
the construction of the BED-DVH's for all of the patients.
Then, in a process similar to that for the C-DVH's, the
BED-DVH's derived from each of the individual dose dis-
tributions were averaged over the six patients in each of
the four groups (grade 0 – rectal, grade 3 – rectal, grade 0
– bladder, and grade 3 – bladder) to produce average
BED-DVH's. The authors are aware of the recent efforts re-
garding advanced modeling concepts for evaluating the
relationship between physical irradiation and biological
damage on normal structures – in particular, BED pro-
vides a measure of biological effect at a point at which it
is calculated – measuring the absolute biological effect
over a volume having a non-uniform dose distribution
formally requires the computation of the equivalent uni-
form dose (EUD) [23]. However, this caveat does not ap-
ply directly to the current task, because the goal of the
current investigation is to use the DVH (constructed using
either conventional dose or BED) as a relative measure of
biological response, not as an absolute measure, and in
this context constructing a DVH from BED computations
and averaging the DVH's (both C-DVH's and BED-DVH's)
over a patient population was felt to be an appropriate
methodology.
After construction of the C-DVH's and BED-DVH's, it was
clear that the general shape of the two were slightly differ-
ent, as would be expected by the non-linear transforma-
tion in Equation (1) above. In order to perform
comparison of the individual matched pairs in an objec-
tive, reproducible, and systematic manner, the following
measure of normalized difference in the average DVH was
computed:
Equation (2) represents an attempt to compress the DVH
difference information into a single quantity, and was felt
to be a valid quantity as the DVH's did not 'cross' – that is,
the grade 3 DVH's were above and to the right of the grade
0 DVH's at all dose (or BED) levels. Furthermore, this ap-
proach was felt to be valid biologically, as integral dose to
critical structures has been correlated by many investiga-
tors with late treatment toxicity [24–30]. The authors are
also aware of the special problems related to applying the
DVH for tubular and surface structures (such as the rec-
tum and bladder) [28,31]. However, because C-DVH's of
the whole organs were used as the basis for the original
clinical decision making on the patient population under
consideration (i.e., those treated before 1999), it was felt
that integral dose to the entire rectum and entire bladder
would be appropriate as one measure for clinical compar-
ison of the use of BED-DVH's versus C-DVH's.
Equation (2) was applied to compute the δAUC's (both for
the C-DVH's and for the BED-DVH's) for each of the six
matched-patient pairs in the rectal toxicity category and to
each of the six matched-patient pairs in the bladder toxic-
ity category. In order to perform a statistical comparison
between these matched-pair δAUC's obtained using C-
DVH's and those obtained using BED-DVH's, the stu-
dent's t-test was used.
Although the treatment decisions were made with knowl-
edge of the integral dose delivered to the critical struc-
tures, the authors recognize that there is controversy with
regard to the classification of biological response of the
normal structures under study in the current investigation.
In particular, many recent reports (e.g., [32]) suggest that
the bladder and rectum may be serial rather than parallel
structures with regard to their biological response to radi-
ation injury. Thus, an alternative measure of merit was
chosen to complement the AUC analysis above. Specifi-
cally, the percent volume receiving above a set high dose
level (in this study, 60 Gy) was analyzed. The analogous
expression to Equation (2) is the following:
Equation (3) was applied in exactly the same manner as
above to compute δV60's for the C-DVH's and BED-DVH's
for both the bladder and rectum. It should be noted that
when applying Equation (3) to the BED-DVH's, the 60 Gy
conventional dose transforms [using Equation (1), as-
suming once-daily 2 Gy fractions] to approximately 100
Gy; thus, V60 on the C-DVH's corresponds to V100 on the
BED-DVH's. The statistical comparison between the
matched-pair δV60's obtained between C-DVH's and BED-
DVH's was performed using the student's t-test.
δ AUC
Area Under Curve AUC in grade 3 patient AUC in grade 
= [] − 0 0 patient




Percent volume receiving 60 Gy in grade 3 patient
=
≥ [] V60 −− ( )
() ()
V60 in grade 0 patient
V60 in grade 0 patient
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Results
As expected, the DVH's (both C-DVH's and BED-DVH's)
were predictive of rectal and urinary toxicity – that is,
those that developed late GI or GU toxicity had DVH's
that demonstrated more integral dose to the rectum or
bladder than those patients who did not develop such tox-
icity. This reinforces and validates the well-known and
widespread use of DVH's in evaluating external beam
[5,24–29] and interstitial [33] treatment plans for pros-
tate cancer patients.
Figure 1 shows the comparison for the case of the conven-
tional DVH's of the rectum. In this figure, the average C-
DVH of the rectum was computed for the 6 patients in the
grade 3 group as well as the 6 patients in the grade 0
group. The average DVH's are displayed – as is demon-
strated, the grade 3 curve is to the right of and above the
grade 0 curve. Similar analyses were done for the BED-
DVH-Rectum (as demonstrated in Figure 2), for the C-
DVH-Bladder (as demonstrated in Figure 3) and for the
BED-DVH-Bladder (as demonstrated in Figure 4). It
should be noted that in all cases, the average grade 3
DVH's – conventional or BED – were consistently above
and to the right of the corresponding grade 0 curve at each
dose (or BED) level from zero to maximum, again validat-
ing the uniform comparison approach summarized in
Equations (2) and (3).
Table 3 shows the results of the detailed matched-pair
AUC analysis. In this table, the δAUC's obtained using the
C-DVH's and BED-DVH's for each of the matched-patient
pairs is displayed. The students' t-test was used to obtain a
p-value for each of the rectal toxicity and bladder toxicity
categories. As Table 3 displays, the δAUC analysis demon-
strates a p-value of 0.036 for the rectal toxicity compari-
son, and a p-value of 0.065 for the bladder toxicity
Figure 1
Average Conventional DVH's for the rectum. Solid = grade 0 toxicity; hashed = grade 3 toxicity.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/16
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comparison, suggesting that [when using AUC as the
measure of merit] the BED-DVH's were significantly bet-
ter-correlated (than the corresponding C-DVH's) with rec-
tal toxicity, and marginally better-correlated with bladder
toxicity.
Table 4 displays the results of the matched-pair V60 anal-
ysis. In this table, the δV60's obtained using the C-DVH's
and BED-DVH's for each of the matched-patient pairs is
displayed. This table demonstrates a p-value of 0.021 for
the rectal toxicity comparison, and a p-value of 0.021 for
the bladder toxicity comparison, suggesting that [when
using V60 as the measure of merit] the BED-DVH's were
significantly better-correlated (than the corresponding C-
DVH's) with rectal toxicity and with bladder toxicity.
Conclusions
The values for δAUC and  δV60 are higher for the BED-
DVH's of the rectum and bladder than for the counterpart
C-DVH's. Because the AUC and V60 are dosimetric end-
points used routinely for the evaluation of radiation treat-
ment plans, this analysis suggests that BED-DVH's for the
rectum and bladder correlate better with late toxicity than
C-DVH's and should be considered when attempting to
minimize late GI and GU toxicity after radiotherapy for
prostate cancer. Because this analysis was performed with
two independent measures of merit of the DVH's – the
AUC and the V60, the early results reported herein appear
promising for the use of BED-DVH's.
Because the patient population having late grade 3/4 tox-
icity (which is a small population but was chosen as the
target population that is most likely to benefit from the in-
corporation of BED-DVH's into the process of treatment
planning) was the focus of this initial investigation, the
number of patients in the current study is understandably
small. Six cases of late grade 3/4 GI toxicity represent ap-
proximately 3% of the study population – this low inci-
Figure 2
Average Biological-Effective DVH's for the rectum. Solid = grade 0 toxicity; hashed = grade 3 toxicity.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/16
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dence also applies to the six cases of late grade 3/4 GU
toxicity. Assuming that the same low rate of late toxicity is
maintained, the number of cases of such late complica-
tions will not increase significantly with a significant in-
crease in size of the study population. Thus, while the
results are encouraging for the correlation of BED-DVH's
to rectal toxicity, the correlation to bladder toxicity using
the integral dose/AUC endpoint did not reach statistical
significance, likely due to the limitations in sample size.
However, because the integral dose/AUC analysis did
reach significance for the rectum, and because the V60
analysis did reach statistical significance for both the blad-
der and rectum, the results of the current investigation
represent initial success with the application of the BED-
DVH concept.
As one means of avoiding the statistical problems posed
by evaluating late toxicity, analyzing early grade 3/4 toxic-
ity, which has a higher incidence, may allow for greater
statistical power in validating the BED-DVH concept.
However, because the modeling for the Tp, alpha, and al-
pha/beta is altogether different for early vs late structures
and because the transformation between late to early pa-
rameters in Equations (1–2) above are nonlinear, the re-
sults of the current analysis (and corresponding
conclusions) may be completely different from such an
early toxicity analysis. For these reasons, the use of BED-
DVH's for evaluating and predicting early GI and GU tox-
icity will be the subject of a separate communication.
The results of the current investigation are encouraging –
the well-known conventional DVH can be successfully ex-
panded to include treatment delivery, tissue biology, and
time/fractionation-related information that better repre-
sents the true effect of the treatment on critical structures.
Other investigators have expanded the C-DVH to include
Figure 3
Average Conventional DVH's for the bladder. Solid = grade 0 toxicity; hashed = grade 3 toxicity.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/16
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Figure 4
Average Biological-Effective DVH's for the bladder. Solid = grade 0 toxicity; hashed = grade 3 toxicity.
Table 3: Matched-pair AUC Analyses using C-DVH and BED-DVH.
δAUC (C-DVH) δAUC (BED-DVH) p-value*
Rectum
Matched Pair 1 0.14 0.11
Matched Pair 2 0.47 0.55
Matched Pair 3 0.11 0.18
Matched Pair 4 0.38 0.46
Matched Pair 5 0.23 0.29
Matched Pair 6 0.03 0.03
Mean 0.23 0.27 0.036
Bladder
Matched Pair 1 0.22 0.23
Matched Pair 2 0.28 0.37
Matched Pair 3 0.19 0.30
Matched Pair 4 0.15 0.23
Matched Pair 5 0.18 0.19
Matched Pair 6 0.18 0.14
Mean 0.20 0.24 0.065BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/16
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functional and spatial information [4,34,35], but the cur-
rent investigation is the first report correlating a DVH which
has been expanded to include BED parameters with late treat-
ment toxicity for prostate cancer irradiation.
Although the initial focus of this investigation was the
study of late radiation effects on the rectum and bladder,
there is no conceptual limitation to the use of the tech-
niques described herein to study early effects of treatment
(for acute toxicity assessment) or to study target structures
(for outcome/survival analysis) at any anatomic site. The
results of the current investigation, while encouraging, are
preliminary and require validation by other investigators
– because of the low incidence of late grade 3/4 complica-
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